NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

NWBO is the 8 track cassette of cancer vaccines IMO
Placebo was better than DCVAX in PFS

One of the leading contenders in the race for a brain tumor vaccine is MimiVax’s SurVaxM. This vaccine candidate targets survivin, a protein that is overexpressed in cancer cells and plays a crucial role in tumor growth and survival. SurVaxM is administered after surgery and radiotherapy when the tumor burden is low, and the immune system is more responsive. The vaccine is given subcutaneously every two weeks for four doses, followed by a maintenance dose every eight weeks thereafter.

The results from MimiVax’s phase 2a trial in newly diagnosed glioblastomas (GBMs) are encouraging. When used as an add-on to standard therapy, SurVaxM demonstrated a median overall survival of 28.4 months from diagnosis